AIGH Capital Management LLC Has $1.43 Million Stock Holdings in KALA BIO, Inc. $KALA

AIGH Capital Management LLC increased its stake in shares of KALA BIO, Inc. (NASDAQ:KALA) by 52.8% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 300,000 shares of the company’s stock after buying an additional 103,650 shares during the period. KALA BIO makes up 0.6% of AIGH Capital Management LLC’s holdings, making the stock its 26th biggest holding. AIGH Capital Management LLC’s holdings in KALA BIO were worth $1,428,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Readystate Asset Management LP bought a new position in shares of KALA BIO in the first quarter worth about $243,000. ADAR1 Capital Management LLC increased its holdings in shares of KALA BIO by 35.7% in the first quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company’s stock valued at $1,713,000 after purchasing an additional 78,582 shares in the last quarter. Finally, Woodline Partners LP bought a new position in KALA BIO in the 1st quarter worth approximately $1,483,000. Institutional investors and hedge funds own 24.61% of the company’s stock.

Insider Buying and Selling at KALA BIO

In related news, major shareholder Bros. Advisors Lp Baker sold 513,607 shares of the stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $1.38, for a total transaction of $708,777.66. Following the completion of the transaction, the insider directly owned 46,480 shares in the company, valued at approximately $64,142.40. This trade represents a 91.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 8.32% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

KALA has been the topic of a number of recent research reports. Oppenheimer increased their price objective on KALA BIO from $15.00 to $33.00 and gave the company an “outperform” rating in a research report on Thursday, September 11th. Mizuho set a $1.50 price target on KALA BIO in a report on Tuesday, September 30th. Lifesci Capital lowered KALA BIO from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. LADENBURG THALM/SH SH cut KALA BIO from a “buy” rating to a “neutral” rating in a report on Monday, September 29th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of KALA BIO in a research note on Monday, September 29th. One analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $20.38.

KALA BIO Price Performance

Shares of KALA stock opened at $1.31 on Monday. KALA BIO, Inc. has a 12-month low of $1.10 and a 12-month high of $20.60. The firm has a fifty day moving average of $9.70 and a 200-day moving average of $6.41. The firm has a market capitalization of $9.20 million, a price-to-earnings ratio of -0.19 and a beta of -2.10. The company has a quick ratio of 2.10, a current ratio of 2.10 and a debt-to-equity ratio of 3.19.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings data on Friday, August 8th. The company reported ($1.71) earnings per share for the quarter, beating the consensus estimate of ($1.82) by $0.11. On average, equities research analysts forecast that KALA BIO, Inc. will post -10.84 earnings per share for the current year.

KALA BIO Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.